Skip to main content

Table 6 Univariate and multivariate analyses for RFS in all patients (n = 1004)

From: Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: a retrospective study of 1004 Chinese breast cancer patients

 

RFS

Univariate analysis

Multivariate analysis

Factors

HR

95%CI

P value

HR

95%CI

P value

Age (> 50y vs ≤ 50y)

0.831

0.632–1.093

0.186

–

–

–

Menopausal status (pre/peri vs post)

1.072

0.793–1.450

0.649

–

–

–

Histological subtype (non-IDC vs IDC)

1.922

1.080–3.419

0.026

2.093

1.184–3.701

0.011

Tumour size (> 5 cm vs ≤ 5 cm)

1.454

1.070–1.976

0.017

1.452

1.073–1.965

0.016

Lymph node involvement (yes vs no)

1.720

1.266–2.338

0.001

1.742

1.282–2.366

<  0.001

Subtype

 HR*(+) HER2 (−)

1

Ref.

Ref.

1

Ref.

Ref.

 HR*(+) HER2 (+)

1.395

0.945–2.059

0.094

1.529

1.033–2.264

0.034

 HR*(−) HER2 (+)

1.930

1.359–2.743

<  0.001

2.195

1.541–3.128

<  0.001

 HR*(−) HER2 (−)

2.430

1.673–3.530

<  0.001

2.843

1.948–4.148

<  0.001

Ki67 index (≤ 14% vs > 14%)

1.271

0.911–1.773

0.157

–

–

0.215

Fib status (high vs low)

1.024

0.754–1.391

0.880

–

–

0.951

pCR (no vs yes)

1.851

1.612–5.487

0.025

1.794

1.051–3.063

0.032

  1. Abbreviations: RFS recurrence-free survival, HR hazard ratio, CI confidence interval, IDC invasive ductal carcinoma, HR* hormone receptor, HER2 human epidermal growth factor receptor 2, Fib fibrinogen, pCR pathological complete response